Alan Breier, MD, Neurology, Indianapolis, IN, Indiana University Health University Hospital

AlanBreierMD

Neurology Indianapolis, IN

Professor of Psychiatry and assumed respoinsibilities as Chief of the Psychotic Disorders Program and Director of Research at Larue Carter hospital

Are you Dr. Breier?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 59 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Alan Breier, MD is a board certified neurologist in Indianapolis, Indiana. He is currently licensed to practice medicine in Indiana, District of Columbia, and Maryland. He is affiliated with Eskenazi Health and Indiana University Health University Hospital.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterRESIDENCY
  • Yale University School of Medicine
    Yale University School of MedicineRESIDENCY
  • Yale-New Haven Hospital
    Yale-New Haven HospitalINTERNSHIP
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1997 - 2021
  • DC State Medical License
    DC State Medical License 1990 - 1997
  • MD State Medical License
    MD State Medical License 1984 - 1998
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501
    BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501July 10, 2018
  • Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
    Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical MeetingsMay 19, 2017
  • Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate
    Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product CandidateSeptember 12, 2016

Hospital Affiliations